Advances in the role of STAT3 in tumor immunology

doi:10.3969/j.issn.1006-7795.2025.03.007

Abstract

Abstract: Signal transducer and activator of transcription 3 (STAT3) are nuclear transcription factors that regulates expression of genes that are involved in cell cycle, cell survival, and cancer-related immune response. Activated STAT3 may participate in oncogenesis by stimulating cell proliferation, resisting apoptosis and promoting tumor angiogenesis and metastasis. Furthermore, abnormal activation of STAT3 is associated with poor tumor prognosis. Recent advances have revealed a crucial role of persistent activation of STAT3 in cancer progression and immune escape. STAT3 is also an important driver of mediated immune escape in tumor immunity, so it has become an effective target in immunotherapy. Therefore, STAT3 became frequently studied targets for more specific cancer immunotherapies. This article elaborated the multiple functions of STAT3 in innate immunity, adaptive immunity and tumor immunity. Further, it put forward to the prospects and issues that urgently need to be addressed in the future.

Key words: signal transducer and activator of transcription, STAT3, immunology, tumor immunology, immunotherapy

CLC Number:

R392.9

Zhang Wenxiu, Xiong Yang, Yu Minghang, Wang Xi. Advances in the role of STAT3 in tumor immunology[J]. Journal of Capital Medical University, 2025, 46(3): 442-447.

References

［1］Witalisz-Siepracka A, Klein K, Zdársky B, et al. The multifaceted role of STAT3 in NK-Cell tumor surveillance［J］. Front Immunol, 2022, 13: 947568.
［2］Ma J H, Qin L, Li X. Role of STAT3 signaling pathway in breast cancer［J］. Cell Commun Signal, 2020, 18(1): 33.
［3］Zou S L, Tong Q Y, Liu B W, et al. Targeting STAT3 in cancer immunotherapy［J］. Mol Cancer, 2020, 19(1): 145.
［4］Jin W. Role of JAK/STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial-mesenchymal transition［J］. Cells, 2020, 9(1): 217.
［5］Amaya M L, Inguva A, Pei S S, et al. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation［J］. Blood, 2022, 139(4): 584－596.
［6］Tošic′ I, Frank D A. STAT3 as a mediator of oncogenic cellular metabolism: pathogenic and therapeutic implications［J］. Neoplasia, 2021, 23(12): 1167－1178.
［7］Huynh J, Chand A, Gough D, et al. Therapeutically exploiting STAT3 activity in cancer － using tissue repair as a road map［J］. Nat Rev Cancer, 2019, 19(2): 82－96.
［8］Xu J N, Lin H F, Wu G, et al. IL-6/STAT3 is a promising therapeutic target for hepatocellular carcinoma［J］. Front Oncol, 2021, 11: 760971.
［9］Wang X, Wang J, Zhao J H, et al. HMGA2 facilitates colorectal cancer progression via STAT3-mediated tumor-associated macrophage recruitment［J］. Theranostics, 2022, 12(2): 963－975.
［10］Liu C, Yao Z Y, Wang J N, et al. Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway［J］. Cell Death Differ, 2020, 27(6): 1765－1781.
［11］Kim S Y, Park S, Kim S, et al. CD133-containing microvesicles promote cancer progression by inducing M2-like tumor-associated macrophage polarization in the tumor microenvironment of colorectal cancer［J］. Carcinogenesis, 2024, 45(5): 300－310.
［12］Shi X, Chen W, Yin Y, et al. RAC1high NK cell-based immunotherapy in hepatocellular carcinoma via STAT3-NKG2D axis［J］. Cancer Lett, 2024, 592: 216909.
［13］Gotthardt D, Putz E M, Straka E, et al. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance［J］. Blood, 2014, 124(15): 2370－2379.
［14］Neo S Y, Tong L, Chong J, et al. Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis［J］. Sci Transl Med, 2024, 16(747): eadi2952.
［15］Chou W C, Levy D E, Lee C K. STAT3 positively regulates an early step in B-cell development［J］. Blood, 2006, 108(9): 3005－3011.
［16］Xiao S X, Fan C B, Ma J L, et al. STAT3 promotes cell proliferation by potentiating the CCL4 transcriptional activity in diffuse large B-Cell lymphoma［J］. Acta Haematol, 2022, 145(4): 371－383.
［17］Hu S F, Ren S, Cai Y Q, et al. Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of wnt－β-catenin-STAT3 signaling［J］. Cell Death Differ, 2022, 29(3): 642－656.
［18］Gao Y M, Ding X J. miR-145－5p exerts anti-tumor effects in diffuse large b-cell lymphoma by regulating S1PR1/STAT3/AKT pathway［J］. Leuk Lymphoma, 2021, 62(8): 1884－1891.
［19］Wang L, Zhou M, Kong X, et al. Specific targeting of STAT3 in B cells suppresses progression of B cell lymphoma［J］. Int J Mol Sci, 2023, 24(17): 13666.
［20］Dong C. Cytokine regulation and function in T cells［J］. Annu Rev Immunol, 2021, 39: 51－76.
［21］Chen X, Ma C N, Li Y M, et al. Trim21-mediated CCT2 ubiquitination suppresses malignant progression and promotes CD4+T cell activation in breast cancer［J］. Cell Death Dis, 2024, 15(7): 542.
［22］Hanna B S, Llaó-Cid L, Iskar M, et al. Interleukin－10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity［J］. Immunity, 2021, 54(12): 2825－2841.e10.
［23］Zhang C Y, Yue C Y, Herrmann A, et al. STAT3 Activation-Induced fatty acid oxidation in CD8+ T effector cells is critical for obesity-promoted breast tumor growth［J］. Cell Metab, 2020, 31(1): 148－161.e5.
［24］Sun Q, Zhao X, Li R, et al. STAT3 regulates CD8+ T cell differentiation and functions in cancer and acute infection［J］. J Exp Med, 2023, 220(4): e20220686.
［25］Ishteyaque S, Singh G, Yadav K S, et al. Cooperative STAT3-NFkB signaling modulates mitochondrial dysfunction and metabolic profiling in hepatocellular carcinoma［J］. Metabolism, 2024, 152: 155771.
［26］Cao T Y, Zhang W Y, Wang Q, et al. Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells［J］. Cell, 2024, 187(9): 2288－2304.e27.
［27］Xu W L, Li S L, Li M, et al. Targeted elimination of myeloid-derived suppressor cells via regulation of the STAT pathway alleviates tumor immunosuppression in neuroblastoma［J］. Immunol Lett, 2021, 240: 31－40.
［28］Oweida A J, Darragh L, Phan A, et al. STAT3 modulation of regulatory T cells in response to radiation therapy in head and neck cancer［J］. J Natl Cancer Inst, 2019, 111(12): 1339－1349.
［29］Manoharan S, Perumal E. A strategic review of STAT3 signaling inhibition by phytochemicals for cancer prevention and treatment: advances and insights［J］. Fitoterapia, 2024, 179: 106265.
［30］Jonker D J, Nott L, Yoshino T, et al. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial［J］. Lancet Gastroenterol Hepatol, 2018, 3(4): 263－270.
［31］Hong D, Kurzrock R, Kim Y, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer［J］. Sci Transl Med, 2015, 7(314): 314ra185.
［32］Odate S, Veschi V, Yan S, et al. Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases neuroblastoma tumorigenicity and increases chemosensitivity［J］. Clin Cancer Res, 2017, 23(7): 1771－1784.
［33］Yoyen-Ermis D, Tunali G, Tavukcuoglu E, et al. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS［J］. Sci Rep, 2019, 9(1): 11697.
［34］Chiba M, Shimono J, Suto K, et al. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma［J］. Blood, 2024, 143(14): 1379－1390.
［35］Brudno J N, Maus M V, Hinrichs C S. CAR T cells and T-cell therapies for cancer: a translational science review［J］. JAMA, 2024, 332(22): 1924－1935.
［36］Kagoya Y, Tanaka S, Guo T X, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects［J］. Nat Med, 2018, 24(3): 352－359.